Other examples of selective RTK inhibitors include those against RET protein, BLU-667 (pralsetinib) and LOXO-292 (selpercatinib), which also demonstrated potent activity against RET fusions and activating mutations across a multitude of cancer types33–35. The gene discussed is RET; the disease is cancer.